JAMA Network
About The Study: The results of this cohort study suggest that there is a decreased risk of skin cancer among patients treated with nicotinamide, with the greatest effect seen when initiated after the first skin cancer. Nicotinamide is a vitamin B3 derivative that is sold as an over-the-counter medication. JAMA Dermatology Editor in Chief Kanade Shinkai, MD, PhD, selected the paper as a highlight for journalists. Once published, the paper will be accompanied by a podcast and short video.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
